PolyPeptide Group AG (PLYGF) reports a 16% revenue increase and significant EBITDA margin improvement, while navigating ...

PolyPeptide surges on strong 2026 margin outlook ...

Continuing GLP-1/GIP agonist therapy prior to elective upper endoscopy increases the risk for residual gastric volume, but clear liquids the day before could mitigate the risk.

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

Lilly’s experimental drug met endpoints for blood-sugar level reduction and weight loss at trial.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Retatrutide demonstrated promising results in its first late-stage trial for Type 2 Diabetes, reducing HbA1c levels by up to ...

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon) receptor agonist.

A new Phase 2 clinical study is now enrolling adults with moderate to severe asthma to evaluate the safety and efficacy of Brenipatide, an investigational, once-weekly subcutaneous injection designed ...

Gilead HPI licensing adds $35M now + $330M milestones; Phase 2 starts by 2026; strong cash runway. Click for this ASMB update ...

For many Americans struggling to lose weight, powerful new medications are changing the game. With roughly 40% of U.S. adults living with obesity, according to the Centers for Disease Control ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...